<p>This week Lori, Greg and Tyler discuss AbbVie: how longtime CEO Richard Gonzalez <a href="https://www.biospace.com/article/abbvie-s-humira-is-a-textbook-case-for-drugmakers-navigating-patent-cliff/" target="_blank" rel="noopener noreferer">navigated Humira&#39;s LOE</a>, his victorious retirement <a href="https://www.biospace.com/article/abbvie-ceo-gonzalez-to-retire-july-1-after-more-than-a-decade-at-helm/" target="_blank" rel="noopener noreferer">announcement</a>, and the future of biosimilars.</p>
<p>Also discussed: Earlybird Health&#39;s <a href="https://www.biospace.com/article/earlybird-health-hopes-to-get-the-worm-with-new-186m-vc-fund/" target="_blank" rel="noopener noreferer">$186m VC fund</a>; and definitely not the IRA.</p>

The gap is where the pain is: Drug pricing and patient costs

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.